Continuation Study for Latozinemab
Trial details
- Registry ID
- NCT06111014
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as AL001
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Continuation Study for LatozinemabNCT06111014 | ALEC | Phase 3 | Terminated | 2025-09-01Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |